Back to Results
First PageMeta Content
Enzymes / Phosphodiesterase inhibitor / Pyridines / CGMP-specific phosphodiesterase type 5 / Phosphodiesterase 2 / Phosphodiesterase / PDE3 inhibitor / Cyclic nucleotide phosphodiesterase / PDE5 inhibitor / Chemistry / Molecular biology / Organic chemistry


Document Date: 2014-03-03 21:03:11

Open Document

File Size: 62,01 KB

Share Result on Facebook

Company

Lundbeck / GlaxoSmithKline / Wiley-VCH Verlag GmbH & Co. KGaA / Bayer / Novartis / Merck / AMP / Asahi Kasei / Envivo Pharmaceuticals / Suzuki / Ó 2014 Wiley-VCH Verlag GmbH & Co. KGaA / /

Currency

pence / /

Event

FDA Phase / /

Facility

Sun Yat-Sen University / /

IndustryTerm

chemical synthesis / n-butyl / treatment of depression / metal binding region / catalytic site / treatment of schizophrenia and Huntington’s disease / treatment of peripheral diseases / treatment of cognitive disorders / /

MedicalCondition

peripheral diseases / atopic dermatitis / schizophrenia / disease / chronic dosing / male erectile dysfunction / malaria / pulmonary arterial hypertension / chronic obstructive pulmonary disease / erectile dysfunction / T cell-related disorders / prostatic hypertrophy / leishmaniasis / Huntington’s disease / sickness / pulmonary hypertension / immunological diseases / cognitive disorders / pain / Chagas disease / renal disease / infection / depression / infectious disease / human African trypanosomiasis / disorders / /

MedicalTreatment

drug therapies / /

Person

Spiros Liras / Andrew S. Bell / /

Product

olanzapine / amrinone / adenosine / Post-2010 / PDE6 / PDE10A / P450 / /

Technology

drug discovery / x-ray / tomography / high-throughput screening / drug design / /

SocialTag